

OCT 10 2006

APR 2

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

PTO/SB/08a (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD

Attorney Docket Number 03-552-C7

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
*	US- 6,174,905		01-16-2001	Suzuki et al.	
*	US- 6,777,217		08-17-2004	Schreiber et al.	
*	US- 6,653,309		11-25-2003	Saunders et al.	
*	US- 5,137,918		08-11-1992	Weisershausen et al.	
*	US- 6,034,251		03-07-2000	Aslanian et al.	
*	US- 5,945,450		08-31-1999	Takenouchi et al.	
*	US- 5,332,750		07-26-1994	Mederski et al.	
*	US- 6,653,309		11-25-2003	Saunders et al.	
*	US- 6,777,217		08-17-2004	Schreiber et al.	
*	US- 5,635,377		06-03-1997	Pederson et al.	
*	US- 5,366,878		11-22-1994	Pederson et al.	
*	US- 5,652,355		07-29-1997	Metelev et al.	
*	US- 2002/0061860		05-23-2002	Li et al.	
*	US- 2003/0232859		12-18-2003	Kozlowski et al.	
*	US- 2003/0096844		05-22-2003	Kozlowski et al.	
*	US- 2004/0186148		09-23-2004	Shankar et al.	
*	US- 2004/0132804		07-08-2004	Tong et al.	
*	US- 2004/0010013		01-15-2004	Friary et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)				
1	WO 04/071400		08/26/2004	Schenzhen Chipscreen Biosciences		
2	WO 04/058234		07/15/2004	Schering Aktiengesellschaft		
3	WO 03/087057		10/23/2003	Astrazeneca UK Limited		
4	JP2003221380		08/05/2003	Nippon Soda Co.		X
5	WO 01/64643 A2		09/07/2001	Cortherapeutics Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD

Attorney Docket Number 03-552-C7

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
*	US-2004/0106599	06-03-2004	Delorme et al.		
*	US-2004/0147569	07-29-2004	Suzuki et al.		
*	US-2005/0096222	05-05-2005	Hidaka et al.		
*	US-2004/0044051	03-04-2004	Kozlowski et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)				
6	WO 01/60354		08/23/2001	Teijin Limited		X Abstract
7	WO 98/45252		10/15/1998	Hoechst Schering Agrevo		
8	WO 01/68585		09/20/2001	Fujisawa Pharmaceutical		X
9	WO 01/38322		05/31/2001	Methylgene Inc.		
10	WO 01/16106		03/08/2001	Schering Aktiengesellschaft		
11	WO 02/069947		09/12/2002	Methylgene Inc.		
12	WO 00/03704		01/27/2000	SmithKline Beecham Corp.		
13	EP 0 657 454		11/14/1994	Merck Patent GmbH		X Abstract
14	EP 0 847 992		09/30/1997	Schering Aktiengesellschaft		
15	WO 03/092686		11/13/2003	Astrazeneca UK Limited		
16	WO 03/087057		10/23/2003	Astrazeneca AB		
17	WO 03/076438		09/18/2003	Janssen Pharmaceutica		
18	WO 03/075929		09/18/2003	Janssen Pharmaceutica		
19	WO 03/076395		09/18/2003	Janssen Pharmaceutica		
20	WO 03/076400		09/18/2003	Janssen Pharmaceutica		
21	WO 03/076401		09/18/2003	Janssen Pharmaceutica		
22	WO 03/076421		09/18/2003	Janssen Pharmaceutica		
23	WO 03/076422		09/18/2003	Janssen Pharmaceutica		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD

Attorney Docket Number 03-552-C7

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)				
24	WO 03/076430		09/18/2003	Janssen Pharmaceutica		
25	CA 2,136,288		11/21/1994	Merck Patent Gesellschaft		
26	EP 1 256 341		11/13/2002	Teijin Limited		
27	JP 2003-137866		05/14/2003	Sankyo Co. Ltd.		X
28	JP 1999-269146		10/05/1999	Mitsui Chemicals Inc.		X
29	JP 1999-302173		11/02/1999	Mitsui Chemicals Inc.		X
30	JP 1996-258863		09/30/1996	Suzuki		X
31	WO 01/70675 A2		09/27/2001	Methylgene, Inc.		
32	WO 03/024448 A2		03/27/2003	Delorme et al.		
33	CA 2,490,579		01/15/2004	Besterman et al.		
34	CA 2,480,356		10/23/2003	Stokes et al.		
35	CA 2,484,065		11/13/2003	Stokes et al.		
36	JP 11269146		10/05/1999	Suzuki et al.		X Abstract
37	WO 04/069133		08/19/2004	F. Hoffman-La Roche AG		
38	WO 04/069823		08/19/2004	Methylgene, Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OCT 10 2006
U.S. PATENT & TRADEMARK OFFICE
Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

PTO/SB/08b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known	
Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	03-552-C7

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Cecil Textbook of Medicine, edited by Bennett, J.C., and Plum F., 20 th Edition, Volume 1, 1004-1010, (1996).	
	2	Ragione, Fulvio Della et al., "Genes Modulated by Histone Acetylation as New Effectors of Butyrate Activity", FEBS Letters 499, 199-204, (2001).	
	3	Turner, W. W. et al., "Recent Advances in the Medicinal Chemistry of Antifungal Agents", Current Pharmaceutical Design, 2, 209-224 (1996).	
	4	Sugar, Alan M. et al., "Comparison of Three Methods of Antifungal Susceptibility Testing with the Proposed NCCLS Standard Broth Macrodilution Assay: Lack of Effect of Phenol Red", Diagn. Microbiol. Infect. Dis., 21, 129-133 (1995)	
	5	Snyder, JW et al., "Common Bacteria Whose Susceptibility to Antimicrobials is no Longer Predictable", J. Med. Liban, 48(4), 208-14 (2000).	
	6	Suzuki, et al., "Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives," Journal of Medicinal Chemistry, American Chemical Society, Washington U.S., Vol. 42, No. 15, 1999, pages 3001-3003.	
	7	Database Crossfire Beilstein (Online) Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE, N,N'-di (o-aminophenyl) terephthalamide, Database accession no. 5619310 XP-002229372, Third invention Abstract & Indian J. Chem. Sect. B., Vol. 25, 1986, pages 1146-1149.	
	8	Database Crossfire Beilstein (Online) Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE, Database accession no. 3016237 XP-002229373, 4, 6-diamino-N, N'-bis-(2-amino-phenyl)-isophthalamide. Third invention abstract & Chem. Heterocycl. Compd. Vol. 13, 1977, pages 1029-1032.	
	9	Database Crossfire Beilstein (Online) Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE, Database accession no. 3458834 XP-002229374, N, N'-bis-(2-amino-phenyl)-phthalamide. Third invention abstract & Justus Liebigs Ann. Chem., Vol. 347, 1906, page 116.	
	10	Picard et al., "Desymmetrization Reactions: A Convenient Synthesis of Aromatic Diamide Diamines" Synthesis, Vol. 10, 2001, pages 1471-1478.	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD

Sheet

2

of

5

Attorney Docket Number 03-552-C7

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Rabilloud G et al., "Réactions de condensation de l'o-phénylenediamine avec les benzoxazin-3, 1-ones-4 substituées en position 2", Bull. Soc. Chim. Fr., 1975, pages 2682-2686.	
	12	Csordas, Adam, "On the Biological Role of Histone Acetylation," Biochem. J., Vol. 265 (1990) pp. 23-38.	
	13	Taunton, Jack, et al. "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p," Science, Vol. 272 (1996) pp. 408-411.	
	14	Grozinger, Christina M., et al., "Three Proteins Define a Class of Human Histone Deacetylases Related to Yeast Hda1p," PNAS, Vol. 96 (1999) pp. 4868-4873.	
	15	Kao, Hung-Ying, et al., "Isolation of a Novel Histone Deacetylase Reveals that Class I and Class II Deacetylases Promote SMRT-Mediated Repression," Genes & Development, Vol. 14 (2000) pp. 55-66.	
	16	Van den Wyngaert, Ilse, et al. "Cloning and Characterization of Human Histone Deacetylase 8," FEBS Letters, Vol. 478 (2000) pp. 77-83.	
	17	Zhou, Xianbo, et al., "Cloning and Characterization of a Histone Deacetylase, HDAC9," PNAS, Vol. 98, No. 19, (2001) pp.10572-10577.	
	18	Kao, Hung-Ying, et al., "Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase," J. Biol. Chem., Vol. 277, No. 1 (2002) pp.187-193.	
	19	Gao, Lin, et al. "Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family," J. Biol. Chem., Vol. 277, No. 28 (2002) pp. 25748-25755.	
	20	Richon, Victoria M., et al. "A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases," PNAS, Vol. 95 (1998) pp. 3003-3007.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

5

<i>Complete if Known</i>	
Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD

Attorney Docket Number 03-552-C7

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	Yoshida, Minoru et al., "Reversible Arrest of Proliferation of Rat 3Y1 Fibroblasts in Both the G1 and G2 Phases by Trichostatin A," Experimental Cell Research, Vol. 177 (1988) pp. 122-131.	
	22	Finnin, Michael S., et al., "Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors," Nature, Vol. 401 (1999) pp. 188-193.	
	23	Yoshida, Minoru, et al., "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both In Vivo and In Vitro by Trichostatin A," J. Biol. Chem., Vol. 265, No. 28 (1990) pp.17174-17179.	
	24	Ramchandani, Shyam, et al., "Inhibition of Tumorigenesis by a Cytosine-DNA, Methyltransferase, Antisense Oligodeoxynucleotide," PNAS, Vol. 94 (1997) pp. 684-689.	
	25	Pon, Richard T., "Solid Phase Supports for Oligonucleotide Synthesis," Methods in Molecular Biology, Vol. 20 (1993) pp.465-496.	
	26	Alaimo, Robert J., "The Preparation and Characterization of 2-Amino-5,6-Dichloro and 2-Amino-6,7-Dichlorobenzothiazole," J. Het. Chem., Vol. 8 (1971) pp.309-310.	
	27	Zee-Cheng, Robert K. Y. et al., "Antileukemic Activity of Substituted Ureidothiazoles, Ureidothiadiazoles, and Related Compounds," J. Med. Chem., Vol. 22, No. 1 (1979) pp. 28-32.	
	28	Taurins, Alfred et al., "Synthesis of Pyridyl- and Quinolyl-Substituted 2-Aminothiazoles," J. Het. Chem., Vol. 7 (1970) pp. 1137-1141.	
	29	Rosowsky, Andre, et al., "5-Deaza-7-Desmethylene Analogues of 5,10-Methylene-5,6,7,8-Tetrahydrofolic Acid and Related Compounds: Synthesis and In Vitro Biological Activity," J. Het Chem., Vol. 31 (1994) pp. 1241-1250.	
	30	Meyer, Thomas, et al., "A Derivative of Staurosporine (CGP 41 251) Shows Selectivity for Protein Kinase C Inhibition and In Vitro Anti-Proliferative as Well as In Vivo Anti-Tumor Activity," Int. J. Cancer, Vol. 43 (1989) pp. 851-856.	

Examiner Signature		Date Considered
--------------------	--	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/574,088
				Filing Date	March 23, 2006
				First Named Inventor	Oscar Moradei
				Art Unit	TBD
				Examiner Name	TBD
Sheet	4	of	5	Attorney Docket Number	03-552-C7

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	31	Anderson, Malcolm, et al., "Imidazo[1,2-a]pyridines: A Potent and Selective Class of Cyclin-Dependent Kinase Inhibitors Identified Through Structure-Based Hybridisation," <i>Bioorganic & Medical Chemistry Letters</i> , Vol. 13 (2003) pp. 3021-3026.		
	32	Zlatoidský, P. et al., "Synthesis of 4-(4-Guanidinobenzoyloxy)Benzamides and 1-(4-Guanidinobenzoyloxy)Benzoyloxy Acetamides as Trypsin Inhibitors," <i>Eur. J. Med. Chem.</i> , Vol. 31 (1996) pp. 895-899.		
	33	Zimmermann, Jürg, et al., "Phenylamino-Pyrimidine (PAP) – Derivates: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 6, No. 11 (1996) pp. 1221-1226.		
	34	Barvian, Mark, et al., "Pyrido[2,3-d]Pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases," <i>J. Med. Chem.</i> , Vol. 44 (2001), pg. 1016.		
	35	Barvian, Mark, et al., "Pyrido[2,3-d]Pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases," <i>J. Med. Chem.</i> , Vol. 43, No. 24 (2000) pp. 4606-4616.		
	36	Piper, James R. et al., "Analogues of Methotrexate in Rheumatoid Arthritis. 2. Effects of 5-Deazaaminopterin, 5,10-Dideazaaminopterin, and Analogues on Type II Collagen-Induced Arthritis in Mice," <i>J. Med. Chem.</i> , Vol. 40, No. 3 (1997) pp. 377-381.		
	37	Grell, Wolfgang, et al., "Repaglinide and Related Hypoglycemic Benzoic Acid Derivatives," <i>J. Med. Chem.</i> , Vol. 41 (1998) pp. 5219-5246.		
	38	Geoffroy, Otto J. et al., "Chemoselective One-Pot Reductive Deamination of Aryl Amines," <i>Tetrahedron Letters</i> , Vol. 42 (2001) pp. 5367-5369.		
	39	Boger, Dale L. et al., "Total Synthesis of Distamycin A and 2640 Analogs: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity," <i>J. Am. Chem. Soc.</i> , Vol. 122 (2000) pp. 6382-6394.		

Examiner Signature		Date Considered
--------------------	--	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

5

Attorney Docket Number

Complete if Known

Application Number	10/574,088
Filing Date	March 23, 2006
First Named Inventor	Oscar Moradei
Art Unit	TBD
Examiner Name	TBD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40	Matsuoka, Hiroharu, et al., "Antirheumatic Agents: Novel Methotrexate Derivatives Bearing a Benzoxazine or Benzothiazine Moiety," J. Med. Chem., Vol. 40 (1997) pp.105-111.	
	41	Hennequin, Laurent F., et al., "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors," J. Med. Chem., Vol. 45 (2002) pp.1300-1312.	
	42	Taylor, Edward C., "Novel 5-Desmethylene Analogues of 5,10-Dideaza-5,6,7,8-Tetrahydrofolic Acid as Potential Anticancer Agents," J. Org. Chem., Vol. 57 (1992) pp. 3218-3225.	
	43	Zhu, Zhijian, et al., "Synthesis of 2,6,7-Trichloro-1-(β-D-Ribofuranosyl)Naphtho[2,3-d]imidazole: A Linear Dimensional Analogue of the Antiviral Agent TCRB," J. Org. Chem., Vol. 63 (1998) pp. 977-983.	
	44	International Search Report for PCT/CA2005/000454 dated August 11, 2005.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.